Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics committee and the Clinical Trials Registry to begin the world's first Phase 2a take-home LSD microdosing trial in patients with Major Depressive Disorder (MDD).

MDD is reportedly the leading cause of global disability, with over 260 million people affected. 

MindBio is viewed as one of the businesses most committed to the advancement of LSD microdosing trials, a psychedelic-based treatment that “proposes to be a globally scalable solution to treating mental health conditions,” as CEO Justin Hanka defined …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.